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Summary
Objective: To investigate the efﬁcacy, safety and the duration of treatment effectiveness of intra-articular hyaluronic acid (Artz, Japan) in
patients with ankle osteoarthritis (OA).
Method: As a prospective clinical trial, 93 patients with unilateral ankle pain for at least 6 months and radiographically classiﬁed as Kellgre-
neLawrence grade I or II ankle OA were included. After ﬁve weekly intra-articular Artz injections, the Ankle Osteoarthritis Scale (AOS), the
American Orthopaedic Foot and Ankle Society (AOFAS) ankle/hindfoot score, ankle sagittal range of motion (ROM), patients’ global satisfac-
tion, local adverse events and consumption of rescue analgesics were analyzed.
Results: Seventy-ﬁve patients completed the study. Signiﬁcant improvement in AOS and AOFAS ankle/hindfoot scores was noted at 1 week,
1 month, 3 months and 6 months post the ﬁfth injection (P< 0.001 compared with baseline). The mean reduction of AOS score was 1.9, 2.6,
2.5 and 2.6 at each following visit (P< 0.001). The mean AOFAS ankle/hindfoot score improved from 64 points at baseline to 75, 78, 78, and
78 points at 1 week, 1 month, 3 months and 6 months, respectively, post the ﬁfth injection (P< 0.001). Ankle sagittal ROM did not improve
signiﬁcantly (P> 0.05). The majority of patients reported satisfaction at 1 week (100%), 1 month (100%), 3 months (90.7%) and 6 months
(86.7%) follow-up. Local adverse events occurred in 6.7% of patients. Acetaminophen consumption dropped signiﬁcantly following treatment
(P< 0.001).
Conclusion: Five weekly intra-articular injections of Artz provide pain relief and functional improvements in patients with KellgreneLawrence
grades I and II ankle OA. The clinical effect was rapid at 1 week and may last for 6 months or more.
ª 2006 OsteoArthritis Research Society International. Published by Elsevier Ltd. All rights reserved.
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Osteoarthritis (OA) is a common progressive degenerative
joint disease with multiple etiologies, but similar biological,
morphological, and clinical outcome1,2. Individuals with
OA might suffer from pain, muscle weakness, loss of joint
range of motion (ROM) and increasing disability. The
disease process of OA is characterized by the progressive
erosion of articular cartilage, leading to joint space narrow-
ing, subchondral sclerosis, subchondral cyst, synovial
inﬂammation and marginal osteophyte formation3.
OA can be a functionally and emotionally limiting condi-
tion for which several treatment options exist. Current
treatment options for OA include the use of simple analge-
sics or nonsteroidal anti-inﬂammatory drugs (NSAIDs),
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Received 2 December 2005; revision accepted 5 March 2006.8intra-articular corticosteroid injections, physiotherapy
(including physical modalities, various stretching or
strengthening exercises, shoe modiﬁcations, boots or assis-
tive devices such as canes or crutches, etc.), weight reduc-
tion, orthotics and surgical treatment4. Prior to surgical
management of OA, which is expensive and not risk-free,
all other treatment options should be fully exploited.
Creamer and Hochberg presented the treatment protocol
of OA and they stated that intra-articular hyaluronic acid
(HA) played an important role1. HA is a high molecular
weight polysaccharide contained within normal endogenous
synovial ﬂuid and it contributes to the elasticity and viscosity
of synovial ﬂuid. HA acts as a ﬂuid shock-absorber and it
helps to maintain the structural and functional characteris-
tics of the cartilage matrix. It also inhibits the formation
and release of prostaglandins, induces proteoglycan aggre-
gation and synthesis, and modulates the inﬂammatory
response5,6. A degradation of HA may be associated with
increased vulnerability to articular cartilage damage. OA
leads to a reduction in both molecular size and concentra-
tion of HA in the synovial ﬂuid6e8. According to Balazs
and colleagues, the injection of HA into joints with OA could
restore the viscoelasticity of the synovial ﬂuid, augment the67
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thesis, inhibit hyaluronate degradation, reduce joint pain,
and improve joint function9,10. Several trials have attempted
to evaluate the effects of intra-articular HA in knee OA11e18.
These studies relied on pain relief, joint function as well as
ROM of the affected joint as parameters for the effective-
ness of such a treatment. Pietrogrande showed a pain
reduction from visual analogue scale values of 6 cm down
to 2 cm 60 days after the intra-articular injections of HA11.
Di Marco and Letizia found a reduction of weight-bearing
pain from 6.7 to 4.7 cm following treatment with HA13.
According to a recent review, intra-articular injection of HA
reduced knee pain in patients with tibiofemoral disease by
20e40% over 6e12 months18. In general, previous trials
have reported that intra-articular HA is a safe and well-
tolerated treatment. OA can occur in several of the
weight-bearing joints of the foot and ankle. To date there
is only limited published literature on its use in the ankle
and no viscosupplements have been approved for osteoar-
thritic joints other than the knee19e21. Theoretically visco-
supplementation is an approach that should apply to all
synovial joints. The clinical success of intra-articular HA in
patients with knee OA suggests this would be a useful
approach worthy of serious clinical investigation.
The purpose of this study was to investigate the efﬁcacy,
safety and the duration of its treatment effectiveness of ﬁve
weekly intra-articular injections of HA in patients with unilat-
eral ankle OA. Joint-speciﬁc functional outcome measures
including the Ankle Osteoarthritis Scale (AOS)22 and the
American Orthopaedic Foot and Ankle Society (AOFAS)
ankle/hindfoot scores23, ankle sagittal ROM24 and patients’
global satisfaction were assessed.
Methods
PATIENTS
Patients in this study were referred from our outpatient
orthopedic department with the diagnosis of unilateral an-
kle OA. All patients reported unilateral ankle pain for at
least 6 months and had either reported no signiﬁcant ben-
eﬁt from conservative treatment (including medication,
physical modalities, various stretching or strengthening ex-
ercises, etc.) or were unable to tolerate side effects of
medications. Ankle radiographs (weight-bearing antero-
posterior and lateral views) taken within 6 months were re-
viewed by one author and were equivalent to grade I or II
by KellgreneLawrence classiﬁcation (grade 1, doubtful
narrowing of joint space and possible osteophytic lipping;
grade 2, deﬁnite osteophytes and possible narrowing of
joint space; grade 3, moderate multiple osteophytes, deﬁ-
nite narrowing of joint space, some sclerosis and possible
deformity of bone contour; and grade 4, large osteophytes,
marked narrowing of joint space, severe sclerosis and def-
inite deformity of bone contour)25. In addition, all patients
in this study (1) had a current total AOS score (described
below) of >3 and <7.5 (possible range, 0e10); (2) were
normally active, not bedridden or conﬁned to a wheelchair,
and were able to walk 30 m without the help of a walker,
crutches, or cane; (3) were willing to discontinue all
NSAIDs or other analgesic medication (except for rescue
medication) for the duration of the study; and (4) did not
receive physical therapy or trial of shoe modiﬁcations or
orthotics for the study period.
Exclusion criteria included pregnant and lactating women,
presence of joint infections of foot or ankle, bilateral ankle
OA requiring treatment of both ankles, signiﬁcant ankledeformity or instability, previous arthroscopy or surgery on
the ankle within 12 months, intra-articular steroid or HA
injection within the past 6 months, had substantial venous
or lymphatic stasis in the legs, treatment with systemic ste-
roid, immunosuppressives or anticoagulants (except for
acetylsalicylic acid at dosages of up to 325 mg/day), history
of rheumatoid arthritis, gout, or any other inﬂammatory
arthropathy, history of chicken or egg allergy, presence of
other comorbidity (neoplasm, diabetes mellitus, paresis,
recent trauma, etc.) or poor health status that would interfere
with the clinical assessments during the study.
Medical records for each patient were reviewed. Baseline
characteristics (age, sex, weight, height, employment status
as light workers or heavy labors, side of involvement, etiol-
ogy of OA and disease duration) were recorded before the
ﬁrst injection. The etiology of OA was determined based on
medical history, physical examination, and imaging studies.
The cause was determined whenever possible. If no cause
could be elucidated, then by a process of elimination, the
case was classiﬁed as OA of unknown etiology.
STUDY DESIGN
This was a prospective clinical trial with a 6-month follow-
up period. The trial was conducted in the outpatient rehabil-
itation department at a university-afﬁliated tertiary care
medical center. The study was approved by the institutional
review board for human investigation and all subjects
provided signed informed consent before being enrolled in
the study.
After completing the baseline survey within 2 weeks of
entry into this study, the patients were then given ﬁve weekly
intra-articular injections of HA. The test medications (Artz)
were provided by Seikagaku Corporation, Tokyo, Japan.
Each ampoule of the active medication contained 25 mg of
sodium HA in 2.5 ml of phosphate buffered saline. The
sodium HA was extracted from rooster combs and the puri-
ﬁed material had a molecular weight of 6.2 105 to
11.7 105 Da. The preparations were injected into the ankle
joints at a dose of one ampoule per week for a total of 5
weeks. The injections were done by an experienced physi-
cian who took no part in the clinical assessment of patients
throughout the study. Either the lateral or medial approach
for injection could be used at the discretion of the injector.
An intake of analgesics or NSAIDs was not permitted and
physical therapy was not carried out during the study period.
Only acetaminophen (500 mg), up to 4 g/day was allowed as
rescue medication. If the treatment dose was above the
stipulated limit (acetaminophen 4 g/day), the patient was
regarded as a clinical failure. Patients taking analgesics or
NSAIDs stopped them at least 7 days before the preinjection
assessment. Administration of acetaminophen 8 h before
the time of follow-up assessment was prohibited. The
administration of all analgesic medications during the study
period was recorded on a diary card by the patient.
CLINICAL ASSESSMENT
The clinical assessment was documented by the same
investigator for every patient prior to the ﬁrst injection and
at intervals of 1 week, 1 month, 3 months and 6 months
post the ﬁfth injection. The clinical assessment included
the following items:
(1) The AOS is a patient-rated, validated outcome mea-
sure that includes nine items on a pain subscale
and nine items on a disability subscale. Using the
869Osteoarthritis and Cartilage Vol. 14, No. 9AOS, a score of 0 represents no pain or disability
and 10 represents worst pain or disability imaginable
(Appendix 1)22.
(2) AOFAS ankle/hindfoot score is a 100-point scale that
devotes 40 points to pain, 50 points to function and 10
points to alignment. The maximum score of 100
points denotes no pain and normal function and align-
ment (Appendix 2)23.
(3) Ankle sagittal ROM was measured with a hand-held
goniometer. The axis of the goniometer is located at
the intersection of the foot and the shank. Measure
ankle dorsiﬂexion and ankle plantar ﬂexion range
while the patient is supine with knee ﬂexed to 90
degrees24. Ankle sagittal ROM is the sum of ankle
dorsiﬂexion and plantar ﬂexion angles.
(4) Patients were asked to rate the level of global satis-
faction with regard to ankle pain relief on weight bear-
ing compared to their preinjection condition at each
follow-up visit. The rating was based on a 7-point
categorical scale weighted from completely satisﬁed,
satisﬁed, somewhat satisﬁed, no change, somewhat
unsatisﬁed, unsatisﬁed to completely unsatisﬁed.
The data of the patients’ global satisfaction are
expressed as the number of the patients in each of
the seven categories.
(5) To monitor the safety of each injection, the occur-
rence of systemic and local adverse events, deﬁned
as any unwanted events whether it was thought to
be related to the study drugs or not, was recorded
on a diary card.
STATISTICAL ANALYSIS
A total of 75 patients completed the study through the
6-month follow-up and the statistical analysis was done
on completers. All statistical procedures were conducted
with the Statistical Package for the Social Sciences (ver-
sion 12.0; SPSS Inc., Chicago, Illinois). Change of out-
come measures was analyzed using paired t test
comparing baseline value with each follow-up score.
P values less than 0.05 were regarded as statistically
signiﬁcant.Results
Ninety-three patients with unilateral OA of the ankle
were recruited in the study. Five patients withdrew from
the study before the ﬁnal injection (one fear of injection,
two moving to another city and two because of trafﬁc ac-
cident and unrelated intercurrent illness). Eleven patients
were lost to follow-up because of noncompliance. Two pa-
tients withdrew from study due to subsequent ankle sur-
gery. A total of 75 participants (34 females; 41 males)
with an average age of 50.2 14.3 years completed the
study. Demographic data and disease characteristics of
the patients were shown in Table I. OA without traceable
history of trauma or purulent arthritis was attributed as
OA of unknown etiology in 23 patients. OA due to ligamen-
tous injury, malleolar fracture, plafond fracture, talar frac-
ture, previous purulent arthritis or other causes were
noted in 52 patients.
Table II provided a summary of outcome measures. Mean
change from baseline in AOS and AOFAS ankle/hindfoot
scores at each following visit was shown in Table III. Ankle
sagittal ROMdid not improve signiﬁcantly following treatment
(P> 0.05). All the other treatment outcomes improved signif-
icantly at each follow-up visit (P< 0.001). These effects were
rapid at 1 week post the ﬁfth injection, and the treatment
effects could last for at least 6 months.
Table I
Demographic data and disease characteristics of the patients
Characteristic Ankle OA
(n¼ 75)
Range
Age (years) 50.2 14.3 22e84
Sex (F/M) 34/41
Weight (kg) 71.5 11.9 50e92
Height (cm) 164.4 7.6 150e176
Employment status
(light worker/heavy labor)
35/40
Side of ankle OA (Lt/Rt) 37/38
Etiology of OA (unknown/known) 23/52
Radiographic stage (KellgreneLawrence stage)
Grade I 32
Grade II 43
Disease duration (years) 5.3 4.7
Data are mean standard deviation.Table II
Summary of outcomes before and after treatment
OA ankle (n¼ 75)
Baseline 1 week 1 month 3 months 6 months P value
Total AOSy 5.1 1.9 3.2 2.1 2.5 2.0 2.6 1.7 2.4 1.9 AB* AC* AD* AE*
Pain subscaley 4.8 1.7 2.8 2.0 2.1 1.7 2.1 1.6 2.1 1.8 AB* AC* AD* AE*
Disability subscaley 5.5 2.4 3.7 2.3 2.9 2.3 3.1 2.1 2.8 2.1 AB* AC* AD* AE*
AOFAS ankle/hindfoot score 64 17 75 15 78 16 78 15 78 14 AB* AC* ADþ AE*
Ankle sagittal ROM 36.9 14.6 37.7 15.0 37.8 14.4 38.1 14.3 38.7 13.6 AB¼ 0.086, AC¼ 0.255,
AD¼ 0.414, AE¼ 0.258
Acetaminophen (tablets/week) 14.3 2.4 5.1 2.3 3.4 2.1 3.1 2.3 3.3 2.2 AB* AC* AD* AE*
Note: Values are the mean standard deviation; AOS¼Ankle Osteoarthritis Scale, AOFAS¼ the American Orthopaedic Foot and Ankle
Society, and ROM¼ range of motion. The possible range for the AOS score was 0e10; the possible range for the AOFAS score was
0e100. *P< 0.001 vs baseline. AB is the comparison before and 1 week after the intra-articular Artz injections; AC is the comparison be-
fore and 1 month after the intra-articular Artz injections; AD is the comparison before and 3 months after the intra-articular Artz injections; and
AE is the comparison before and 6 months after the intra-articular Artz injections.
yHigher scores represent worse pain or function.
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ability were shown in Table II. The average pain subscale
score of AOS prior to injection was 4.8 1.7 cm. The
score decreased to 2.8 2.0, 2.1 1.7 and 2.1 1.6 cm
at 1 week, 1 month and 3 months after the ﬁfth injection
(P< 0.001 for each score compared with baseline), the
reduction remained signiﬁcant until 6 months post the ﬁfth
injection (P< 0.001) (Table II). Improvement in average
disability subscales score of AOS from 5.5 2.4 cm at
baseline to 3.7 2.3, 2.9 2.3 and 3.1 2.1 cm was
noted at 1 week, 1 month and 3 months, respectively,
post the ﬁfth injection (P< 0.001 for each score compared
with baseline). The beneﬁt also persisted to 6 months
(P< 0.001) (Table II). The mean reduction of total AOS
score was 1.9, 2.6 and 2.5 at 1 week, 1 month and 3
months, respectively, after the ﬁfth injection (P< 0.001
for each score compared with baseline). The effect still re-
mained signiﬁcant at the 6-month follow-up (P< 0.001)
(Table III).
The mean AOFAS ankle/hindfoot score improved from
64 17 out of 100 points at baseline (higher score better)
to 75 15, 78 16, 78 15 and 78 14 out of 100 points,
respectively, at 1 week, 1 month, 3 months and 6 months
after the ﬁfth injection (P< 0.001). The improvement in
AOFAS score averaged 14 points at the 6-month follow-
up (P< 0.001) (Table II).
After treatment, ankle sagittal ROM increased in 48 of the
75 patients. ROM decreased in 12 patients and remained
unchanged in 15 patients at the 6-month follow-up. Average
Table III
Mean change from baseline in AOS and AOFAS ankle/hindfoot
scores at each postinjection following visit
Total
AOSy
Pain
subscaley
Disability
subscaley
AOFAS
ankle/
hindfoot
score
1 week 1.9 1.0* 2.0 1.2* 1.8 1.1* 11 9*
1 month 2.6 1.6* 2.7 1.4* 2.5 2.0* 14 8*
3 months 2.5 1.6* 2.7 1.8* 2.4 1.8* 14 10*
6 months 2.6 1.8* 2.8 2.0* 2.5 2.0* 14 11*
AOS¼Ankle Osteoarthritis Scale; and AOFAS¼ the American
Orthopaedic Foot and Ankle Society ankle/hindfoot score. The
possible range for the AOS score was 0e10; the possible range
for the AOFAS ankle/hindfoot score was 0e100. *P< 0.001 vs
baseline.
yHigher scores represent worse pain or function.
Table IV
Satisfaction to viscosupplementation for the treatment of ankle OA
Completely
satisﬁed
Satisﬁed Somewhat
satisﬁed
No
change
Satisfaction
rate (%)
1 week 32 24 19 0 100
1 month 29 29 17 0 100
3 months 22 24 22 7 90.7
6 months 22 24 19 10 86.7
Numbers referred to number of patients who reported their level
of global satisfaction with regard to pain relief on weight bearing
when comparing the situation after viscosupplementation with that
before injection. No patients reported dissatisfaction throughout
the study period.ankle sagittal ROM increased 1.8 degrees, but this change
in ROM from baseline was not statistically signiﬁcant
(P> 0.05) (Table II).
Patient satisfaction is a fundamental goal in the treat-
ment of OA. Satisfaction reﬂects the summation of all fac-
tors relating to successful clinical treatment. Results of
patients’ global satisfaction with regard to pain relief on
weight bearing were shown in Table IV. Treatment of
the ankles in this series resulted in high patients’ satisfac-
tion. At 1-week follow-up, 32 patients reported completely
satisﬁed, 24 reported satisﬁed and 19 reported somewhat
satisﬁed. The overall satisfaction rate was 100%. A shift in
distribution of patients to different categories was ob-
served at 1 and 3 months. At 6 months post the ﬁfth in-
jection, the reported satisfaction slightly diminished as
22 patients reported completely satisﬁed, 24 satisﬁed
and 19 somewhat satisﬁed. Ten patients reported no
change compared to their preinjection condition. Sixty-
ﬁve patients were satisﬁed with their overall response to
treatment and the overall satisfaction rate was 86.7%.
No patients reported dissatisfaction or aggravations of
the ankle symptoms compared to preinjection condition
throughout the study period.
The injections were well tolerated. Five patients experi-
enced transient pain and erythema at the injection site
that resolved within 48 h and did not interfere with the
remaining injections. The local adverse reaction rate was
5.3% per injection and 6.7% per patient. No case of septic
arthritis or other severe systemic adverse events was
observed during the study.
Patients who received intra-articular HA injections used
much less rescue analgesics during the study period. Acet-
aminophen consumption fell from an average of 14 tablets
weekly at baseline to 5, 3, 3 and 3 tablets weekly at
1 week, 1 month, 3 months and 6 months, respectively,
post the ﬁfth injection (P< 0.001 at each time point
compared with baseline) (Table II).
Discussion
This prospective, open pilot study in patients with unilat-
eral ankle OA had demonstrated that a regimen of ﬁve
weekly intra-articular injections of Artz was safe and efﬁ-
cacious in the areas of pain and ankle function. The
patients’ satisfaction rate was high with only relatively
few local adverse events. These effects were rapid at 1
week post the ﬁfth injection and could last for 6 months
or more.
In this study, the average pain subscale score decreased
signiﬁcantly from 4.8 cm before injection to 2.1 cm at 6
months post the ﬁfth injection. It appeared that the pain re-
lief reported in previous studies of HA in knee OA was also
documented in this study of ankle OA.
The duration of treatment effectiveness after HA is un-
clear. Most studies report that clinical improvement begins
with a delayed onset between 2 and 5 weeks, lasting 6
months or up to 1 year26e28. In this ankle OA study, we
demonstrated that the clinical effect was rapid at 1 week
and may last for 6 months or more. The mechanisms by
which HA mediates their clinical beneﬁt seem to be multi-
factorial and biologically related, in contrast to the notion
that they provide only viscous ﬂuid replacement. Studies
have shown that the half-life of injected HA may be as
short as 2 days29. Multiple injections attempt to increase
its residence time within the joint. Temporary restoration
of the rheologic homeostasis may trigger normal native
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by reducing white cell aggregation and activation. With
this postulated disease-modifying behavior, its clinical ef-
fects may persist beyond its physical duration within the
joint6,15,28,30.
Most patients in this study with KellgreneLawrence
grade I or II ankle OA had good response to viscosupple-
mentation. This suggested that viscosupplementation was
effective in mild to moderate ankle OA. Whether severe
cases would likely respond to viscosupplementation
remained unknown. Neustadt reported that intra-articular
HA was an effective and safe treatment for pain in
difﬁcult-to-treat patients with moderate to severe OA of
the knee31. Evanich et al. recommended that patients
with a complete collapse of joint space not to receive
this treatment given their poor clinical response32. Theo-
retically, patients with severe OA might have a poor
and shorter response. In future studies, we would like
to recruit patients with higher X-ray grades to see
whether intra-articular HA injections can improve function
in severely obliterated ankle joints. As the treatment
group increases, additional studies should better elucidate
favorable patient response factors that may identify pa-
tients with OA who would beneﬁt the most from
viscosupplementation.
Evaluation of adverse reactions is important because
untoward effects may limit the use of a speciﬁc treatment
option. Signiﬁcant and frequently occurring adverse reac-
tions likely would prohibit the use of a certain modality,
no matter how great the beneﬁt. A wide range of local
adverse reaction rates had been reported after intra-artic-
ular HA. For the ﬁve individual Artz trials, the incidence
varies from 1 adverse event/589 (0.17%) to 11 adverse
events/215 (5.1%)33. Altman and Moskowitz described in-
jection site pain in 23% of knees treated with HA, 13%
with saline placebo, and 9% with subcutaneous local an-
esthesia16. Lussier et al. reported an adverse reaction
rate of 2.7% per injection and 8.3% per patient, most
effects were mild to moderate local reactions14. In this
ankle OA study, local pain of varying intensity and ery-
thema at the injection site occurred in ﬁve patients, but
was mild and resolved within 48 h without sequela in
all cases. The adverse reaction rate was 5.3% per injec-
tion and 6.7% per patient. The occurrence of adverse
events was difﬁcult to predict. They sometimes occurred
after several injections without any reaction previously,
and sometimes they did not occur in subsequent injec-
tions. Interestingly, we found that local adverse reactions
did not predict treatment failure. All of these patients
received subsequent injections and they still improved
clinically and reported high satisfaction. The tolerability
and safety of the treatment regimen were shown in the
study.
The result of the study using HA in the ankle is consis-
tent with previously published studies using HA in the
knee. The study results provide important information for
patients who suffer from OA of the ankle. As surgery to
treat ankle OA is often quite painful, HA may offer pa-
tients who may not have had success with traditional
pain medications, another option to treat their OA. This
study is encouraging as it stimulates interest in research
to assess the potential role of viscosupplementation in
treating ankle OA and it continues to build on the existing
data suggesting beneﬁts from the use of HA in the treat-
ment of joints other than the knees.
Several limitations existed in the study. One limitation
includes the absence of a control group, thus the placeboeffects associated with joint injections were not investi-
gated. Several previous trials have used saline controls
without report of adverse responses; some researchers
speculate that saline injection might have a clinical bene-
ﬁt. We did not make use of a saline control group since
saline injection could not be excluded as a source of
a noxious stimulus and we thought it would be inappropri-
ate and ethically difﬁcult to subject these patients to
a placebo. The very early signiﬁcant beneﬁts with high
satisfaction rate reported in the treatment course with
HA are a remarkable achievement. However, it might
also suggest possibility of a strong placebo effect. The
patients and the injector were not blinded throughout
the study period. The injector, however, did not take
part in analysis of the data. Since the numbers of patients
studied were relatively small, the results were not ana-
lyzed on the basis of severity of OA, cause of OA, or pre-
injection functional levels. The postinjection period was
also not controlled for subject activity level or assistive
devices usage. These factors might have a role in deter-
mining the candidates who would beneﬁt most from this
treatment and might help determine the best overall treat-
ment plan for these patients. Failure to perform a dose
response assessment is another limitation of this study.
Large, randomized clinical trials that carefully assess
clinical outcomes are necessary in order to establish
the efﬁcacy.
A typical Artz treatment cycle for knee OA consists of
ﬁve injections given at weekly intervals by a doctor. The
effectiveness of a single treatment cycle or less than
three injections has never been established. Cost-effec-
tive issues need to be addressed, particularly as ﬁve in-
jections are administered in our study. The long-term
clinical beneﬁt and the reduced apparent need for medi-
cations or alternative OA-modifying therapies might con-
tribute to favorable cost/beneﬁt ratio of this therapy.
Many clinical uncertainties on the use of HA remain.
Future studies regarding optimal number of injections in
a course of treatment, optimal dosing per injection,
different concentration and molecular weight options for
long-term effect of HA as well as the biochemical, mor-
phologic, and histopathologic effects on cartilage are war-
ranted. Comparison studies with other treatment options,
such as intra-articular steroid injections and NSAIDs, are
also needed.
Conclusion
On the basis of this prospective clinical trial of patients
with unilateral KellgreneLawrence grades I and II ankle
OA, we concluded that ﬁve weekly intra-articular injections
of HA provided pain relief and functional improvements
with high patients’ satisfaction. It was a useful and well-
tolerated treatment with rapid onset of action at 1 week
post the ﬁfth injection and the treatment effects lasted for
6 months or longer.
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Ankle Osteoarthritis Scale
Pain
The line next to each item represents the amount of pain
you typically had in each situation. On the far left is ‘‘No
pain’’ and on the far right is ‘‘ The worst pain imaginable’’.
Place a mark on the line to indicate how bad your ankle
pain was in each of the following situations during the
past week. If you were not involved in one or more of these
situations, mark that item NA.
How severe was your ankle pain No pain Worst pain imaginable NA
1. At its worst? -------
2. Before you get up in the morning? -------
3. When you walked barefoot? -------
4. When you stood barefoot? -------
5. When you walked wearing shoes? -------
6. When you stood wearing shoes? -------
7. When you walked wearing shoe inserts or braces? -------
8. When you stood wearing shoe inserts or braces? -------
9. At the end of the day? -------
____/____==______%
Disability
The line next to each item represents the amount of difﬁculty
you had performing an activity. On the far left is ‘‘No difﬁculty’’
and on the far right is ‘‘ So difﬁcult unable’’. Place a mark on
the line to indicate how much difﬁculty you had performing
each activity because of your ankle during the past week.
If you did not perform an activity during the past week, place
an ‘‘X’’ in the column under the heading NA.
How much difficulty did you have No difficulty So difficult unable NA
1. Walking around the house? -------
2. Walking outside on uneven ground? -------
3. Walking four or more blocks? -------
4. Climbing stairs? -------
5. Descending stairs? -------
6. Standing on tip toes? -------
7. Getting out of a chair? -------
8. Climbing up or down curbs? -------
9. Walking fast or running? -------
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AOFAS ankle/hindfoot score (100 points total)
Pain (40 points)
None 40
Mild, occasional 30
Moderate, daily 20
Severe, almost always present 0
Function (50 points)
Activity limitations, support requirement
BNo limitations, no support 10
BNo limitation of daily activities, limitation
of recreational activities, no support
7
BLimited daily and recreational activities, cane 4
BSevere limitation of daily and recreational
activities, walker, crutches, wheelchair, and brace
0
Maximum walking distance, blocks
BGreater than 6 5
B4e6 4
B1e3 2
BLess than 1 0
Walking surfaces
BNo difﬁculty on any surface 5
BSome difﬁculty on uneven terrain, stairs, inclines,
and ladders
3
BSevere difﬁculty on uneven terrain, stairs, inclines,
and ladders
0
Gait abnormality
BNone, slight 8
BObvious 4
BMarked 0
Sagittal motion (ﬂexion plus extension)
BNormal or mild restriction (30( or more) 8
BModerate restriction (15e29() 4
BSevere restriction (less than 150) 0
Hindfoot motion (inversion plus eversion)
BNormal or mild restriction (75e100% normal) 6
BModerate restriction (25e74% normal) 3
BMarked restriction (less than 25% normal) 0
Ankle/hindfoot stability (anteroposterior, varusevalgus)
BStable 8
BDeﬁnitely unstable 0
Alignment (10 points)
BGood, plantigrade foot, ankle/hindfoot well aligned 10
BFair, plantigrade foot, some degree of ankle/
hindfoot malalignment observed, no symptoms
5
BPoor, nonplantigrade foot, severe malalignment,
symptoms
0
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